Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine

European Journal of Endocrinology

Volumn 134, Issue 4, 1996, Pages 454-456

  Delgrange, Etienne ^a   Maiter, Dominique ^b   Donckier, Julian ^a  

^a University Hospital   (Belgium)

^b Hôpital Saint Luc   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MALE; NAUSEA; PRIORITY JOURNAL; PROLACTINOMA;

EID: 0029950870     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340454     Document Type: Article

References (16)

1. Levy A, Lightman SL. Diagnosis and management of pituitary tumours. Br Med J 1994;308:1087-91
2. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumour shrinkage. Endocr Rev 1992;13:220-40
3. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-9
4. Mattei AM, Ferrari C, Barolid P, Cavioni V, Paracchi A, Galparoli C, et al. Prolactin lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrin Metab 1988;66: 193-8
5. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-9
6. Melis GB, Mais V, Gambacciani M, Sghedoni D, Paoletti AM, Fioretti P. Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil Steril 1989;52: 412-5
7. Ferrari C, Paracchi A, Mattei AM, de Vincentis S, D'Alberton A, Crosignani PG. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992;126:489-94
8. Jones TH, Fraser RB. Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. Br J Obstet Gynaecol 1994;101: 349-50
9. Page SR, Nussey SS. Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. J Obstet Gynecol 1989;10: 156-8
10. Cicarelli E, Giusti M, Miola C, Potenzoni F, Sghetoni D, Camanni F, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989;69:725-8
11. Webster J, Piscitelli G, Polli A, D'Alberton A, Falsetti L, Ferrari C, et al. The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol 1993;39:323-9
12. Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G. Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 1990;13:419-22
13. Ferrari C, Piscitelli G, Crosignani PG. Cabergoline: a new drug for the treatment of hyperprolactinaemia. Hum Reprod 1995;10: 1647-52
14. Vilar L, Burke CW. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant to bromocriptine. Clin Endocrinol 1994;41:821-6
15. Van der Lely AJ, Brownell J, Lamberts SWJ. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991;72: 1136-41
16. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J. et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577-84